Brian Ogilvie

Graduate Student - Parkinson Lab
BA, Molecular Biology, William Jewell College

I am originally from the Kansas City area, and currently live in Shawnee, KS.  For several years now I have worked with Andrew Parkinson (formerly a tenured professor in the department) at XenoTech, LLC, where I worked as a study director for in vitro drug-drug interaction studies to support IND and NDA submissions of drug candidates from both biotech and mid-size to large pharmaceutical companies.

Research Interests

My research interests include mechanism-based inhibition of CYP2C19 by proton pump inhibitors (omeprazole and esomeprazole in particular), the CYP-mediated oxidative metabolism of glucuronides and other conjugates, as well as inhibition of CYP enzymes by these conjugates. 

Under the supervision of Andrew Parkinson and Curtis Klaassen, I am continuing to provide mechanistic insight into other, as yet unexplained, drug-drug interactions, such as that between omeprazole and clopidogrel. 

Selected Publications

Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, Toren P and Parkinson A (2011) The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metab Dispos 39:2020-2033.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Paris BL, Holsapple J, Toren P, Otradovec SM and Ogilvie BW (2011) An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome p450 enzymes. Drug Metab Dispos 39:1370-1387.

Watanabe T, Kusuhara H, Debori Y, Maeda K, Kondo T, Nakayama H, Horita S,Ogilvie BW, Parkinson A, Hu Z and Sugiyama Y (2011) Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos 39:1031-1038.

Parkinson A, Ogilvie BW, Paris BL, Hensley TN, Loewen GJ. (2010) Human Biotransformation, in: Biotransformation and Metabolite Elucidation of Xenobiotics (Nassar AF, ed.), John Wiley & Sons, Hoboken, NJ, 1-78.

Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, Paris BL (2010) System-dependent outcomes during the evaluation of drug candidates as Inhibitors of cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT) enzymes: Human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet, 25:16-27.

Hirouchi M, Kusuhara H, Onuki R, Ogilvie BW, Parkinson A and Sugiyama Y. (2009) Construction of triple-transfected cells (OATP1B1/MRP2/MRP3 and OATP1B1/MRP2/MRP4) for analysis of the sinusoidal function of MRP3 and MRP4. Drug Metab Dispos 37:2103-2111.

Paris BL, Ogilvie BW, Scheinkoenig JA, Ndikum-Moffor F, Gibson R and Parkinson A. (2009) In vitro inhibition and induction of human liver cytochrome P450 (CYP) enzymes by milnacipran. Drug Metab Dispos 37:2045-2054.

Nassar AF, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW and Parkinson A. (2009) An in vitro evaluation of the victim and perpetrator potential of the anti-cancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 (CYP) enzymes. Drug Metab Dispos 37:1922-1930.

Ogilvie BW, Usuki E, Yerino P and Parkinson A.  (2008) In Vitro Approaches for Studying the Inhibition of Drug-Metabolizing Enzymes and Identifying the Drug-Metabolizing Enzymes Responsible for the Metabolism of Drugs (Reaction Phenotyping) with Emphasis on Cytochrome P450, in: Drug-Drug Interactions(Rodrigues AD, ed.), Informa Healthcare, New York, 231-358.

Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, Parkinson A.  (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: Implications for drug-drug interactions.  Drug Metab Dispos 34(1):191-197.

Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie BW, Parkinson A, Antonian L.  (2006) Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416.  Toxicol In Vitro. 20(2): 154-62.

Last modified: ,



Brian Ogilvie
Graduate Student - Parkinson Lab

XenoTech, LLC
16825 W. 116th St
Lenexa, KS 66219

P: (913) 227-7137
F: (913) 227-7100